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Abstract: Elevated blood glucose concentrations (BG) (Hyperglycaemia) are a common complication of 
prematurity in extremely low birth weight neonates in the neonatal intensive care unit (NICU), and are 
associated with increased mortality and morbidity. Insulin therapy allows glucose tolerance and weight gain 
to be increased. However, insulin therapy is commonly associated with a significant increase in low BG 
events (hypoglycaemia), which is also associated with adverse outcomes. Controlling BG levels via nutrition 
restriction reduces infant growth and is thus undesirable. STAR (Stochastic TARgeted) is a model-based 
glycaemic framework that mitigates the risks of hypoglycaemia through quantification of current insulin 
sensitivity and future variability. From August 2008 to December 2012 40 patients totaling 61 glycaemic 
episodes were treated with STAR in the NICU (STAR-NICU). Percentage time in the clinically targeted 4.0-
8.0 mmol/L band was 62%, a 14% increase compared to retrospective data and hyperglycaemia 
(BG>10.0mmol/L) was halved. Overall incidence of severe hypoglycemia (BG<2.6 mmol/L) was slightly 
increased from 0.4% to 0.7%, and a concomitant increase in the number of patients experiencing severe 
hypoglycaemia (8 of 62 control episodes in comparison to 1 of 25 retrospective). Results from 5 patient 
episodes under the new STAR-GRYPHON protocol were significantly better, with 83% of measurements 
in the targeted band (35% better than retrospective data and 17% better than original STAR NICU protocols), 
and 0% incidence of BG<4.0 mmol/L. STAR-GRYPHON is expected to maintain this level of tight 
glycaemic control. Thus, model based control can be safely and effectively used to control BG in extremely 
premature infants in intensive care.
     
 
